Navigation Links
Data Analyses Outline Efficacy and Safety of Mircera for the,Treatment of Renal Anemia Associated With Chronic Kidney Disease

ORLANDO, Fla. and NUTLEY, N.J., April 12, 2007 /PRNewswire-FirstCall/ -- Data analyses from the largest initial registration clinical trial program ever undertaken in the renal anemia arena provide efficacy and safety information on the investigational anemia therapy MIRCERA(TM) for the treatment of renal anemia associated with chronic kidney disease (CKD) in patients on dialysis and not on dialysis. Three data analyses were presented at the National Kidney Foundation 2007 Spring Clinical Meetings in Orlando, Florida.

According to these analyses, MIRCERA with extended dosing up to once every four weeks: (1) corrected and maintained hemoglobin (Hb) levels in patients with CKD, on dialysis and not on dialysis; (2) maintained Hb levels in dialysis patients, regardless of congestive heart failure (CHF) status as shown in a post-hoc analysis; and (3) exhibited a safety profile that is consistent with that of commercially available erythropoiesis stimulating agents (ESAs) and typical of those associated with this patient population.

"The goal in treating renal anemia is to safely maintain target hemoglobin levels," said Steven Fishbane, MD, Associate Director of Nephrology, Associate Chairman of the Department of Medicine, and Director of End-Stage Renal Disease research at Winthrop University Hospital. "These data analyses clearly demonstrate that MIRCERA corrected low hemoglobin levels, and maintained target hemoglobin levels with the added convenience of up to once- monthly dosing."

About the Studies

Safety and Tolerability of C.E.R.A. In Patients With Chronic Kidney Disease: Pooled Data From Ten Phase II-III Trials

Pooled data from four Phase II and six Phase III studies evaluated the safety and tolerability of MIRCERA (intravenous (IV) and subcutaneous (SC)) in patients not previously treated with commercially available ESAs and those previously treated with commercially availa
'"/>




Page: 1 2 3 4

Related medicine technology :

1. New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release Tablets as Effective Treatment for Schizophrenia
2. New Long-Term Data Analyses for Bifeprunox Show Favorable Effects Versus Placebo in Stabilized Patients with Schizophrenia
3. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
4. Safety Analyses of Clinical Data for Bifeprunox in Patients with Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar to Placebo
5. Lipitor Significantly Lowered Hospitalization Costs for Patients with Heart Disease, Two New Analyses Show
6. Prospective Model Outlined Potential Time and Cost Savings of Once-Monthly Anemia Treatment
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
10. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
11. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
Post Your Comments:
(Date:5/23/2013)... TUCSON, Ariz. , May 23, 2013 ... world,s first and only FDA, Health Canada and CE ... announced today that the Glasgow Science Centre in ... visitors annually, is featuring the SynCardia temporary Total ... as part of its $3 million Bodyworks Exhibition, one ...
(Date:5/23/2013)... -- InspireMD, Inc. ("InspireMD" or the ... protection stents, today announced new 6-month results from ... trial demonstrating that the MGuard Embolic Protection Stent ... in all-cause mortality in ST segment elevation myocardial ... presented at the InspireMD STEMI Symposium at EuroPCR, ...
(Date:5/23/2013)...  PAREXEL International Corporation (NASDAQ: PRXL ) ... Jefferies Healthcare Conference in New York.  James ... Officer, will be making a presentation on PAREXEL and ... 3, 2013. A live webcast of the ... PAREXEL,s website at www.PAREXEL.com in the Upcoming ...
Breaking Medicine Technology:Glasgow Science Centre Features SynCardia Total Artificial Heart in $3 Million Exhibition 2Glasgow Science Centre Features SynCardia Total Artificial Heart in $3 Million Exhibition 3InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 2InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 3InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 4InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 5PAREXEL International To Present At Jefferies Healthcare Conference 2
... Switzerland, September 16 Mymetics,Corporation (OTCBB: MYMX), ... their preliminary SHIV challenge results on non-human ... vaccine designed,for triggering mucosal protection. The results ... 70% effectiveness to be considered as a,promising ...
... of non-inferiority to a rapid-acting ... ... MNKD ) today released preliminary top-line results from,a Phase 3 clinical ... (Study 009). This study compared the safety and,efficacy of prandial inhalations ...
Cached Medicine Technology:Successful Results for Mymetics Corporation's Mucosal HIV/AIDS Vaccine Viral Challenge Significantly Exceeds Expectations 2Successful Results for Mymetics Corporation's Mucosal HIV/AIDS Vaccine Viral Challenge Significantly Exceeds Expectations 3Successful Results for Mymetics Corporation's Mucosal HIV/AIDS Vaccine Viral Challenge Significantly Exceeds Expectations 4MannKind Reports Positive Data from a Phase 3 Clinical Study of Technosphere Insulin in Type 1 Diabetes 2MannKind Reports Positive Data from a Phase 3 Clinical Study of Technosphere Insulin in Type 1 Diabetes 3MannKind Reports Positive Data from a Phase 3 Clinical Study of Technosphere Insulin in Type 1 Diabetes 4MannKind Reports Positive Data from a Phase 3 Clinical Study of Technosphere Insulin in Type 1 Diabetes 5
(Date:5/23/2013)... journal Science published an article about bexarotene ... an important starting point for further Alzheimer,s research. The ... at VIB and KU Leuven in collaboration with ... and scientists at Janssen Pharmaceutica, Beerse, also tested this ... results were different, as were those of two American ...
(Date:5/23/2013)... - Even while being dragged to its destruction ... fires away, sending signals that thwart the development ... reported in an early online publication at ... often encountered by tumors, the epidermal growth factor ... an international team led by scientists at The ...
(Date:5/23/2013)... 23, 2013 The Rottenstein Law Group ... has created the Tylenol Lawsuit Information Center at ... users and those who are considering filing lawsuits. ... potentially cause severe liver damage, according to a 2009 ... In the “safety communication,” the FDA warned consumers against ...
(Date:5/23/2013)... The vast majority of Americans believe ... over their level of physical activity, the healthfulness of ... actually taking that control. Those are among the ... 2013 Food & Health Survey. , According to the ... have “a great deal of control” or “complete control” ...
(Date:5/23/2013)... 2013 Jeanne Ettelson, president of ... popular and only free OCD support group in Chicago. ... for OCD sufferers, the group is lead by psychologists ... This allows group participants to learn accurate information ... Prevention. , “Participants in Beyond OCD’s support group ...
Breaking Medicine News(10 mins):Health News:New insights contradict promising Alzheimer's research 2Health News:When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs 2Health News:When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs 3Health News:Rottenstein Law Group LLP Now Accepting Tylenol Cases, Announces New Tylenol Lawsuit Information Center 2Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 2Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 3Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 4Health News:Beyond OCD Support Group Marks Fifth Anniversary 2
... 12 (HealthDay News) -- The U.S. Department of Health and ... $185 million to 13 states and the District of Columbia ... cornerstone of President Obama,s health care reform -- across the ... the plan, which will include tax relief to give families ...
... (HealthDay News) -- Dogs can teach children about responsibility, ... maintain their reading skills. Researchers found that reading ... some second-graders, ability to read and their attitude about ... adults experienced declines in both areas, the study found. ...
... -- Although being physically active is one of the best ... ability to get around, a new study shows that people ... thought. Researchers from Northwestern University Feinberg School of Medicine ... of men with knee osteoarthritis are basically "couch potatoes," and ...
... Aug. 12 (HealthDay News) -- Monthly premiums for individual health ... vary widely from state to state, a new report says. ... $136 a month in Alabama to more than $400 a ... the non-profit Kaiser Family Foundation. The foundation said the ...
... published in the American Journal of Industrial Medicine ... of the New York City Fire Department (FDNY) resulting ... David J. Prezant, MD, Chief Medical Officer, FDNY, researchers ... 11, 1994, and September 10, 2008, comparing the total ...
... Hawn Foundation, will present a lecture for the public ... jointly sponsored by the New York Academy of Sciences ... about the MindUP curriculum, the Foundation,s signature educational initiative ... emotional learning program designed for pre-kindergarten through eighth-grade children, ...
Cached Medicine News:Health News:Feds Outline Rules for States' Insurance Exchanges 2Health News:Fido's New Forte: Helping Kids Learn to Read 2Health News:Many Arthritis Patients May Not Be Exercising Enough 2
... determination of Estradiol (E2) concentration in human serum ... hormone with a phenolic A ring. This ... It is the most potent natural Estrogen, ... smaller amounts by the adrenal cortex, and the ...
... The DSL-10-39100 3rd Generation Estradiol ... estradiol in serum. Estradiol measurements ... and treatment of various hormonal ... placental function in complicated pregnancy. ...
... has been useful in the differential diagnosis ... with chest pain. 18-20 ... of sensitive and specific biomarkers, such as ... kinase (CK-MB), and myoglobin, are increased in ...
... is the most potent, naturally secreted estrogen ... the ovary [1]. In the ovary, estradiol ... estrone, a less potent estrogen derived from ... many body tissues. In men, small amounts ...
Medicine Products: